$15 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$210 MillionTotal revenue in the last quarter.
$62.2 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$4.39Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
74.58xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$61.3 MillionEarnings before interest expenses and taxes in the last quarter.
1,371The number of full time employees.
Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
A new research report on the global cardiac assist devices market gives readers a complete guide to the market scenario and its forecast for the period 2017-2027. It is an in-depth analysis of the ...OpenPR, 2 months ago
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASD...Stocks News Feed, 3 months ago
Abiomed, Inc. (NASDAQ:ABMD) VP Andrew J. Greenfield sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $321.00, for a t...Watchlist News, 4 months ago